Welcome to our dedicated page for Jazz Pharmaceuticals Plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), reported a transaction on 09/14/2025. The Form 4 shows 15,647 ordinary shares were disposed under code F(1) at a price of $126.16 per share. The filing explains the shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
After the withholding, Mr. Cozadd beneficially owns 414,326 ordinary shares (reported as direct ownership). The Form 4 was signed on 09/17/2025 by an attorney-in-fact, and the reporting person is identified with an address in Dublin and relationship as Director.
Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), reported a transaction on 09/14/2025. The Form 4 shows 15,647 ordinary shares were disposed under code F(1) at a price of $126.16 per share. The filing explains the shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
After the withholding, Mr. Cozadd beneficially owns 414,326 ordinary shares (reported as direct ownership). The Form 4 was signed on 09/17/2025 by an attorney-in-fact, and the reporting person is identified with an address in Dublin and relationship as Director.
Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), reported two open-market sales executed under a Rule 10b5-1 trading plan on 09/02/2025. The filings show sales of 3,000 ordinary shares at $127.23 (leaving 432,973 shares beneficially owned) and 3,000 ordinary shares at $130.00 (leaving 429,973 shares beneficially owned) after each reported transaction. The report was signed by an attorney-in-fact on behalf of Mr. Cozadd on 09/04/2025 and includes a statement that the transactions were effected pursuant to a Rule 10b5-1 trading plan.
Kenneth W. O'Keefe, identified as a director of Jazz Pharmaceuticals (JAZZ), reported both a grant of restricted stock units and a sale of ordinary shares. On 08/07/2025 he was granted 3,507 restricted stock units under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; each unit represents a contingent right to one ordinary share and, subject to continuous service and conditions, vests in full on July 24, 2026. The next day, 08/08/2025, he sold 1,805 shares at $111.2502 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units. Following these transactions the reporting person beneficially owns 28,672 shares directly, and 4,445 shares indirectly through The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which he is trustee and beneficiary.
Jennifer E. Cook, a director of Jazz Pharmaceuticals (JAZZ), reported equity activity involving restricted stock units and a share sale on Form 4. The filing shows a grant of 3,507 restricted stock units under the company's director award plan; each unit represents a contingent right to one ordinary share and the units vest in full on July 24, 2026 subject to continuous service and plan conditions. Following that grant the reported beneficial ownership rose to 12,642 ordinary shares.
The filing also discloses a sale of 1,805 shares at a price of $111.2494 described as shares sold to satisfy tax obligations arising from vesting of previously granted restricted stock units, leaving 10,837 shares beneficially owned by the reporting person after the sale.
Patrick Enright, identified as a director of Jazz Pharmaceuticals (JAZZ), was granted 3,507 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one ordinary share and, subject to continued service and other conditions, the units will vest in full on July 24, 2026. The filing also reports a sale of 1,805 ordinary shares on 08/08/2025 at $111.2491 to satisfy tax obligations arising from the vesting of previously granted RSUs. The reported direct beneficial ownership rose to 28,184 shares following the RSU grant and declined to 26,379 shares after the tax-related sale.
Laura Hamill, a director of Jazz Pharmaceuticals (JAZZ), reported two related transactions. On 08/07/2025 she was granted 3,507 restricted stock units under the issuer's non-employee directors stock award plan; each unit represents a contingent right to one ordinary share and the units are scheduled to vest in full on July 24, 2026, subject to continued service and plan conditions. On 08/08/2025 she sold 1,805 shares to satisfy tax obligations arising from prior RSU vesting at a reported price of $111.2502 per share. Reported beneficial ownership was 8,738 shares after the grant and 6,933 shares after the sale. These filings reflect routine director compensation and a sell-to-cover tax transaction.
Patrick Kennedy, a director of Jazz Pharmaceuticals (JAZZ), received a grant of 3,507 restricted stock units under the issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to one ordinary share upon vesting; the units will vest in full on July 24, 2026 subject to the reporting person's continuous service and additional conditions.
Following the grant activity, the reporting person sold 1,959 shares at $111.2506 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units, which reduced beneficial ownership from 8,661 shares to 6,702 shares.
Heather McSharry, a director of Jazz Pharmaceuticals (JAZZ), received 3,507 restricted stock units on 08/07/2025 under the company's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each unit is a contingent right to one ordinary share and, subject to continued service and conditions, will vest in full on 07/24/2026.
On 08/08/2025 she sold 1,959 ordinary shares at $111.2497 per share to satisfy tax obligations arising from prior RSU vesting, leaving her with 20,449 ordinary shares beneficially owned (direct) following the reported transactions.
Anne O'Riordan, a director of Jazz Pharmaceuticals plc (JAZZ), filed a Form 4 reporting a grant of restricted stock units and a sale to cover taxes. On 08/07/2025 she was granted 3,507 restricted stock units under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; each unit represents a contingent right to one ordinary share and these units vest in full on July 24, 2026 subject to continuous service and additional conditions. On 08/08/2025 she sold 1,805 shares at $111.2494 per share to satisfy tax obligations arising from the vesting of previously granted RSUs. The filing shows beneficial ownership of 18,305 shares following the grant and 16,500 shares following the sale. The Form 4 was signed by an attorney-in-fact on 08/11/2025.
Norbert G. Riedel, a director of Jazz Pharmaceuticals (JAZZ), reported changes in his beneficial ownership on Form 4. On 08/07/2025 he was granted 3,507 restricted stock units under the issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; each unit represents a contingent right to one ordinary share and the units vest in full on July 24, 2026. On 08/08/2025 he sold 1,805 ordinary shares at $111.2498 per share to satisfy tax obligations arising from prior RSU vesting, with 7,024 shares reported as beneficially owned directly after the sale. The filing also discloses 10,630 shares beneficially owned indirectly by the Norbert G. Riedel 2023 Trust. The Form 4 was signed by attorney Adam Guttmann on 08/11/2025.